Search Within

Martin Henner Voss

  1. "2016"
Formats
  1. Meeting Abstract (15)
  2. Journal Article (13)
Groups
  1. Department of Medicine (28)
  2. Genitourinary Oncology Service (28)
  3. Solid Tumor Oncology Division (28)
  4. Human Oncology and Pathogenesis Program (10)
  5. Department of Pathology and Laboratory Medicine (9)
  6. Epidemiology and Biostatistics (9)

More Groups

People
  1. James Hsieh (16)
  2. Robert Motzer (16)
  3. Yingbei Chen (8)
  4. Abraham Hakimi (7)
  5. Chung-Han Lee (6)
  6. Darren Feldman (6)

More People

Years
  1. 2016 (28)
Publications
  1. Journal of Clinical Oncology (8)
  2. BJU International (5)
  3. Annals of Oncology (2)
  4. Journal for ImmunoTherapy of Cancer (2)
  5. Bladder Cancer (1)
  6. British Journal of Cancer (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (8)
  2. Wiley Blackwell (6)
  3. Biomed Central Ltd (3)
  4. Nature Publishing Group (3)
  5. Oxford University Press (3)
  6. American Association for Cancer Research (2)

More Publishers

Results (28)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Baseline lactate dehydrogenase (LDH) and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with everolimus (EVE) versus sunitinib (SUN): Predictive biomarker analysis from the RECORD-3 trial
    Meeting Abstract

    Voss, M. H.; Chen, D.; Marker, M.; Knox, J.; Hsieh, J.; Voi, M.; Motzer, R. J.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC)
    Meeting Abstract

    Meric-Bernstam, F.; Tannir, N. M.; Mier, J. W.; DeMichele, A.; Telli, M. L.; Fan, A. C.; Munster, P. N.; Carvajal, R. D.; Orford, K. W.; Bennett, M. K.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Medullary renal cell carcinoma (RCC): Genomics and treatment outcomes
    Meeting Abstract

    Carlo, M. I.; Chen, Y.; Chaim, J.; Coskey, D. T.; Woo, K.; Hsieh, J.; Voss, M. H.; Feldman, D. R.; Motzer, R. J.; Lee, C. H.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • CX-839-004: A phase I/II study of the safety, pharmacokinetics, and pharmacodynamics of the glutaminase inhibitor CB-839 combined with nivolumab in patients with renal cell carcinoma, melanoma, and non-small cell lung cancer
    Meeting Abstract

    Lam, E.; Tannir, N. M.; Meric-Bernstam, F.; Vaishampayan, U.; Orford, K. W.; Molineaux, C.; Gross, M.; MacKinnon, A.; Voss, M.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Phase I study of everolimus in combination with gemcitabine and split-dose cisplatin in advanced urothelial carcinoma
    Journal Article

    Abida, W.; Milowsky, M. I.; Ostrovnaya, I.; Gerst, S. R.; Rosenberg, J. E.; Voss, M. H.; Apolo, A. B.; Regazzi, A. M.; McCoy, A. S.; Boyd, M. E.; more...
    Bladder Cancer (2016)

    Fulltext@MSK | Save
  • Updated results from a phase I study of nivolumab (nivo) in combination with ipilimumab (ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study
    Meeting Abstract

    Hammers, H.; Plimack, E. R.; Infante, J. R.; Rini, B. I.; McDermott, D.; Lewis, L.; Voss, M. H.; Sharma, P.; Pal, S. K.; Razak, A.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC)
    Meeting Abstract

    Meric-Bernstam, F.; Tannir, N.; Harding, J.; Voss, M.; Mier, J.; DeMichele, A.; Munster, P.; Patel, M.; Iliopoulos, O.; Owonikoko, T.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • Updated results from a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: The CheckMate 016 study
    Meeting Abstract

    Hammers, H. J.; Plimack, E. R.; Infante, J. R.; Rini, B. I.; McDermott, D. F.; Lewis, L. D.; Voss, M. H.; Sharma, P.; Pal, S. K.; Razak, A.; more...
    BJU International (2016)

    Fulltext@MSK | Save
  • A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mRCC) versus standard of care (SOC)
    Meeting Abstract

    Voss, M.; Hutson, T. E.; Hussain, A.; Vaishampayan, U.; Vogelzang, N. J.; Crowell, T.; Li, J.; Downing, W.; Senderowicz, A.; Stone, E.
    BJU International (2016)

    Fulltext@MSK | Save
  • Medullary renal cell carcinoma (RCC): Genomics and treatment outcomes
    Meeting Abstract

    Lee, C. H.; Carlo, M.; Chen, Y.; Chaim, J.; Coskey, D.; Woo, K.; Voss, M.; Hsieh, J.; Feldman, D.; Motzer, R.
    BJU International (2016)

    Fulltext@MSK | Save